375 related articles for article (PubMed ID: 15846471)
1. Investigation of solubility and dissolution of a free base and two different salt forms as a function of pH.
Li S; Wong S; Sethia S; Almoazen H; Joshi YM; Serajuddin AT
Pharm Res; 2005 Apr; 22(4):628-35. PubMed ID: 15846471
[TBL] [Abstract][Full Text] [Related]
2. Effect of chloride ion on dissolution of different salt forms of haloperidol, a model basic drug.
Li S; Doyle P; Metz S; Royce AE; Serajuddin AT
J Pharm Sci; 2005 Oct; 94(10):2224-31. PubMed ID: 16136556
[TBL] [Abstract][Full Text] [Related]
3. Solution-mediated phase transformation of salts during dissolution: investigation using haloperidol as a model drug.
Greco K; Mcnamara DP; Bogner R
J Pharm Sci; 2011 Jul; 100(7):2755-68. PubMed ID: 21328581
[TBL] [Abstract][Full Text] [Related]
4. Effect of diffusion layer pH and solubility on the dissolution rate of pharmaceutical bases and their hydrochloride salts. I: Phenazopyridine.
Serajuddin AT; Jarowski CI
J Pharm Sci; 1985 Feb; 74(2):142-7. PubMed ID: 3989682
[TBL] [Abstract][Full Text] [Related]
5. Solution-mediated phase transformation of haloperidol mesylate in the presence of sodium lauryl sulfate.
Greco K; Bogner R
AAPS PharmSciTech; 2011 Sep; 12(3):909-16. PubMed ID: 21732157
[TBL] [Abstract][Full Text] [Related]
6. Importance of using physiologically relevant volume of dissolution medium to correlate the oral exposure of formulations of BMS-480188 mesylate.
Gu CH; Gandhi RB; Tay LK; Zhou S; Raghavan K
Int J Pharm; 2004 Jan; 269(1):195-202. PubMed ID: 14698591
[TBL] [Abstract][Full Text] [Related]
7. Investigation of possible solubility and dissolution advantages of cocrystals, I: Aqueous solubility and dissolution rates of ketoconazole and its cocrystals as functions of pH.
Vasoya JM; Shah AV; Serajuddin ATM
ADMET DMPK; 2019; 7(2):106-130. PubMed ID: 35350544
[TBL] [Abstract][Full Text] [Related]
8. Effect of diffusion layer pH and solubility on the dissolution rate of pharmaceutical acids and their sodium salts. II: Salicylic acid, theophylline, and benzoic acid.
Serajuddin AT; Jarowski CI
J Pharm Sci; 1985 Feb; 74(2):148-54. PubMed ID: 3989683
[TBL] [Abstract][Full Text] [Related]
9. The preparation and evaluation of salt forms of linogliride with reduced solubilities as candidates for extended release.
Chrzanowski FA; Ahmad K
Drug Dev Ind Pharm; 2017 Mar; 43(3):421-431. PubMed ID: 27808569
[TBL] [Abstract][Full Text] [Related]
10. Salt formation to improve drug solubility.
Serajuddin AT
Adv Drug Deliv Rev; 2007 Jul; 59(7):603-16. PubMed ID: 17619064
[TBL] [Abstract][Full Text] [Related]
11. Dissolution rates of doxycycline free base and hydrochloride salts.
Bogardus JB; Blackwood RK
J Pharm Sci; 1979 Sep; 68(9):1183-4. PubMed ID: 41085
[TBL] [Abstract][Full Text] [Related]
12. Supersolubilization and amorphization of a model basic drug, haloperidol, by interaction with weak acids.
Singh S; Parikh T; Sandhu HK; Shah NH; Malick AW; Singhal D; Serajuddin AT
Pharm Res; 2013 Jun; 30(6):1561-73. PubMed ID: 23430485
[TBL] [Abstract][Full Text] [Related]
13. pH-Solubility Profiles of Organic Bases and Their Hydrochloride Salts.
Serajuddin AT; Mufson D
Pharm Res; 1985 Mar; 2(2):65-8. PubMed ID: 24272610
[TBL] [Abstract][Full Text] [Related]
14. Salt screening and characterization for poorly soluble, weak basic compounds: case study albendazole.
Paulekuhn GS; Dressman JB; Saal C
Pharmazie; 2013 Jul; 68(7):555-64. PubMed ID: 23923637
[TBL] [Abstract][Full Text] [Related]
15. Role of salt and excipient properties on disproportionation in the solid-state.
Guerrieri P; Taylor LS
Pharm Res; 2009 Aug; 26(8):2015-26. PubMed ID: 19507008
[TBL] [Abstract][Full Text] [Related]
16. Solubility-pH profile of desipramine hydrochloride in saline phosphate buffer: Enhanced solubility due to drug-buffer aggregates.
Marković OS; Pešić MP; Shah AV; Serajuddin ATM; Verbić TŽ; Avdeef A
Eur J Pharm Sci; 2019 May; 133():264-274. PubMed ID: 30914359
[TBL] [Abstract][Full Text] [Related]
17. The use of inorganic salts to improve the dissolution characteristics of tablets containing Soluplus®-based solid dispersions.
Hughey JR; Keen JM; Miller DA; Kolter K; Langley N; McGinity JW
Eur J Pharm Sci; 2013 Mar; 48(4-5):758-66. PubMed ID: 23348153
[TBL] [Abstract][Full Text] [Related]
18. Characterization of Solid Dispersion of Itraconazole Prepared by Solubilization in Concentrated Aqueous Solutions of Weak Organic Acids and Drying.
Parikh T; Sandhu HK; Talele TT; Serajuddin AT
Pharm Res; 2016 Jun; 33(6):1456-71. PubMed ID: 26951566
[TBL] [Abstract][Full Text] [Related]
19. Modifying the diffusion layer of soluble salts of poorly soluble basic drugs to improve dissolution performance.
Hawley M; Morozowich W
Mol Pharm; 2010 Oct; 7(5):1441-9. PubMed ID: 20731341
[TBL] [Abstract][Full Text] [Related]
20. Continuous Preparation of 1:1 Haloperidol-Maleic Acid Salt by a Novel Solvent-Free Method Using a Twin Screw Melt Extruder.
Lee HL; Vasoya JM; Cirqueira ML; Yeh KL; Lee T; Serajuddin AT
Mol Pharm; 2017 Apr; 14(4):1278-1291. PubMed ID: 28245127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
